Mouawad R, Ichen M, Rixe O, Benhammouda A, Vuillemin E, Weil M, Khayat D, Soubrane C
Department of Medical Oncology, Salpetrière Hospital, Paris, France.
Clin Exp Immunol. 1994 Sep;97(3):342-6. doi: 10.1111/j.1365-2249.1994.tb06092.x.
Using flow cytometry, cellular IL-2 receptors were studied before and following chemoimmunotherapy combination in 20 patients with metastatic malignant melanoma (MMM). Patients received cisplatin (100 mg/m2) at days 1 and 28, recombinant IL-2 by continuous infusion from days 3 to 6, 17 to 21, 31 to 34, and 45 to 49. Interferon-alpha (IFN-alpha) was given subcutaneously three times weekly. In terms of clinical response, we observed 55% objective response (complete: 15%). When pretreatment blood samples were compared with those of healthy donors, we did not observe any change in low (alpha chain) and high affinity receptor (alpha + beta) expression. In contrast, intermediate affinity p75 (beta chain) expression was decreased significantly (P < or = 0.0001) in MMM patients. During treatment, we found a dramatic increase of beta chain as well as high affinity (alpha + beta) expression in responding patients, as soon as IL-2 therapy began. Furthermore, the increase of beta chain expression was limited to natural killer (NK) cells (CD56+). In non-responding patients, on the other hand, increase of both receptors was seen only at day 31. These data suggest the involvement of beta chain expression in the mechanism of cell activation after chemoimmunotherapy. Moreover, this early beta chain expression is correlated with the clinical response to chemoimmunotherapy.
采用流式细胞术，对20例转移性恶性黑色素瘤（MMM）患者化疗免疫联合治疗前后的细胞白细胞介素-2受体进行了研究。患者在第1天和第28天接受顺铂（100mg/m²）治疗，从第3天至第6天、第17天至第21天、第31天至第34天以及第45天至第49天持续输注重组白细胞介素-2。α干扰素（IFN-α）每周皮下注射3次。在临床反应方面，我们观察到55%的客观缓解率（完全缓解：15%）。当将预处理血液样本与健康供体的样本进行比较时，我们未观察到低亲和力（α链）和高亲和力受体（α + β）表达有任何变化。相比之下，MMM患者中中等亲和力的p75（β链）表达显著降低（P≤0.0001）。在治疗期间，我们发现，一旦开始白细胞介素-2治疗，缓解患者的β链以及高亲和力（α + β）表达就会急剧增加。此外，β链表达的增加仅限于自然杀伤（NK）细胞（CD56+）。另一方面，在无反应的患者中，仅在第31天观察到两种受体的增加。这些数据表明β链表达参与了化疗免疫治疗后的细胞激活机制。此外，这种早期的β链表达与化疗免疫治疗的临床反应相关。
